Clinical trials: Nab-paclitaxel
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.
The purpose of this study is to determine the recommended dose of TBI-1401(HF10) treatment in combination with chemotherapy (Gemcitabine + Nab-paclitaxel or TS-1) in patients with stage III or IV unresectable pancreatic cancer.
- Trial name
- NCT03252808
- Testing
- TBI-1401(HF10), Gemcitabine, Nab-paclitaxel
- Where
- 8 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Takara Bio Inc.
Metastatic Solid Tumors
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations.
- Trial name
- AURORAS-1 (NCT06983743)
- Testing
- ERAS-0015, ERAS-0015 in combination
- Where
- 9 sites in United States
- Volunteers
- 600 people
- Sponsor
- Erasca, Inc.
Pancreatic Cancer
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, in…
- Trial name
- NCT05859750
- Testing
- AK104, Gemcitabine, Nab-Paclitaxel
- Where
- 7 sites in China
- Volunteers
- 78 people
- Sponsor
- Akeso
Metastatic Pancreatic Ductal Adenocarcinoma
Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
The purpose of this Phase 1b/2 study is to evaluate the safety and tolerability of PF-04136309 in combination with nab-paclitaxel and gemcitabine, characterize the dose-limiting toxicities (DLTs) and overall safety profile of…
- Trial name
- CCR2i (NCT02732938)
- Testing
- PF-04136309, Nab-paclitaxel, Gemcitabine
- Where
- 18 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pfizer
Adenocarcinoma, Carcinoma, Pancreatic Ductal
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic…
- Trial name
- NCT07259317
- Testing
- Relacorilant, Nab-paclitaxel, Gemcitabine
- Where
- 20 sites in United States
- Volunteers
- 80 people
- Sponsor
- Corcept Therapeutics
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Triple Negative Breast Cancer
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
The aim of the study is to evaluate the efficacy and safety of SKB264 as first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast cancer (TNBC) whose tumors do not express programmed cell…
- Trial name
- NCT06279364
- Testing
- SKB264, Paclitaxel, Nab-paclitaxel
- Where
- China
- Volunteers
- 537 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Advanced Pancreatic Cancer
Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer
Assessment of safety and tolerability of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in subjects with Advanced Pancreatic Carcinoma.
- Trial name
- NCT02101580
- Testing
- ADI-PEG 20
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Polaris Group
Triple-Negative Breast Cancer (TNBC)
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
This trial is a registrational Phase III, randomized, open-label, multicenter study designed to compare the efficacy and safety of BL-B01D1 in combination with a PD-1 monoclonal antibody versus nab-paclitaxel in combination with…
- Trial name
- NCT07729956
- Testing
- BL-B01D1, PD-1 monoclonal antibody, Nab-paclitaxel
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma, Pancreatic Cancer
A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
This study is a trial of dexanabinol in patients with advanced tumours. The purposes of the protocol are to study different doses of the study drug to determine the maximum safe dose of the drug given in combination with standard…
- Trial name
- NCT02423239
- Testing
- Dexanabinol, Sorafenib, Nab-paclitaxel
- Where
- 13 sites in Germany, Poland and 2 more
- Volunteers
- 112 people
- Sponsor
- e-Therapeutics PLC
Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available…
- Trial name
- ASCENT-07 (NCT05840211)
- Testing
- Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel
- Where
- 288 sites in United States, Argentina and 26 more
- Volunteers
- 654 people
- Sponsor
- Gilead Sciences
Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
- Trial name
- POD1UM-304 (NCT04205812)
- Testing
- Retifanlimab, Pemetrexed, Cisplatin
- Where
- 140 sites in United States, Brazil and 15 more
- Volunteers
- 583 people
- Sponsor
- Incyte Corporation
Metastatic Pancreatic Cancer
QUILT-3.088: NANT Pancreatic Cancer Vaccine
QUILT-3.088 NANT Pancreatic Cancer Vaccine: Phase II Randomized Trial of the NANT Pancreatic Cancer Vaccine vs. Standard-of-Care as First- Line Treatment for Patients with Metastatic Pancreatic Cancer.
- Trial name
- NCT03563144
- Testing
- Gemcitabine, Nab-paclitaxel, Aldoxorubicin HCl
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Pancreatic Ductal Adenocarcinoma
A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy
This study is open to adults with advanced pancreatic cancer for whom previous treatment was not successful or no treatment exists.
- Trial name
- NCT06528093
- Testing
- BI 765883, Gemcitabine, Nab-paclitaxel
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumor, Cholangiocarcinoma
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors (solid tumor, BTC and…
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer
- Trial name
- NCT05253053
- Testing
- TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
- Where
- 9 sites in China
- Volunteers
- 84 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Carcinoma, Pancreatic Ductal
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
This is a randomized, open-label, multi-center, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal…
- Trial name
- CanStem111P (NCT02993731)
- Testing
- Napabucasin, Nab-paclitaxel, Gemcitabine
- Where
- 267 sites in United States, Australia and 18 more
- Volunteers
- 1,134 people
- Sponsor
- Sumitomo Pharma America, Inc.
Advanced Pancreatic Cancer
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination…
- Trial name
- ARC-8 (NCT04104672)
- Testing
- AB680, Zimberelimab, Nab-paclitaxel
- Where
- 9 sites in United States
- Volunteers
- 196 people
- Sponsor
- Arcus Biosciences, Inc.
Solid Tumor
IN10018 Combination Therapy in Previously-treated Solid Tumors
This is a phase Ib/II, randomized, open-label, multicenter clinical trial to evaluate the antitumor activities, safety, tolerability and pharmacokinetics (PK) of IN10018 in combination with taxane and anti-PD-1/L1 monoclonal…
- Trial name
- NCT05982522
- Testing
- IN10018, Nab-paclitaxel, Tislelizumab
- Sponsor
- InxMed (Shanghai) Co., Ltd.
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with…
- Trial name
- NCT07111832
- Testing
- SHR-A1811 for Injection, SHR-1316 Injection, Toripalimab Injection
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Pancreatic Cancer
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care first line therapy and chemotherapy.
- Trial name
- NCT03136406
- Testing
- Cyclophosphamide, Oxaliplatin, Capecitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- ImmunityBio, Inc.